The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model
Open accessAbstract
Among the earliest and most important stages during tumorigenesis is the activation of the angiogenic process, an event that is termed the “switch to the angiogenic phenotype.” We have developed an in vivo system that can reliably recapitulate the stages in tumor development that represent this transition. Using this model, we have harvested and studied tumor nodules that can be distinguished from each other on the basis of their degree of vascularization. Angiogenic tumor nodules were characterized by the presence of capillary vessels as determined by factor VIII immunohistochemistry, and both angiogenic and proteolytic activities in vitro . In contrast, preangiogenic nodules were devoid of microvessels and showed little angiogenic or proteolytic activity in vitro . Addition of a specific metalloproteinase inhibitor resulted in the abrogation of both angiogenic and proteolytic activities of the angiogenic nodules in vitro . Comparative substrate gel electrophoresis detected the presence of a prominent matrix metalloproteinase (MMP-2) in the angiogenic nodules when compared with the preangiogenic ones. Suppression of MMP-2 activity by antisense oligonucleotides in the vascular nodules resulted in the loss of angiogenic potential both in vitro and in vivo in the chick chorioallantoic membrane assay. Moreover, this suppression of MMP-2 activity in angiogenic nodules inhibited tumor growth in vivo by approximately 70%. These results strongly implicate the activity of MMP-2 as a requirement for the switch to the angiogenic phenotype and validate this model as a reliable and reproducible tool by which to study other cellular and biochemical factors involved in the acquisition of the angiogenic phenotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma
Weidner, N., Semple, J. P., Welch, W. R., & Folkman, J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101033240101 · Cited by 5,627
Nagase, H., & Woessner, J. F. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.21491 · Cited by 3,912
O'Reilly, M. (1994) · Cell · doi:10.1016/0092-8674(94)90200-3 · Cited by 3,345
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Induction of angiogenesis during the transition from hyperplasia to neoplasia
Folkman, J., Watson, K., Ingber, D., & Hanahan, D. (1989) · Nature · doi:10.1038/339058a0 · Cited by 1,879
Vu, T. H., Shipley, J. M., Bergers, G., Berger, J. E., Helms, J. A., Hanahan, D., Shapiro, S. D., Senior, R. M., & Werb, Z. (1998) · Cell · doi:10.1016/s0092-8674(00)81169-1 · Cited by 1,750
Ausprunk, D. H., & Folkman, J. (1977) · Microvascular Research · doi:10.1016/0026-2862(77)90141-8 · Cited by 1,281
Voyta, J. C., Via, D. P., Butterfield, C. E., & Zetter, B. R. (1984) · The Journal of cell biology · doi:10.1083/jcb.99.6.2034 · Cited by 1,239
Self-citationProcessing of tumour necrosis factor-α precursor by metalloproteinases
Gearing, A. J. H., Beckett, P., Christodoulou, M., Churchill, M., Clements, J., Davidson, A. H., Drummond, A. H., Galloway, W. A., Gilbert, R., Gordon, J. L., et al. (1994) · Nature · doi:10.1038/370555a0 · Cited by 1,194
Vlodavsky, I., Folkman, J., Sullivan, R., Fridman, R., Ishai-Michaeli, R., Sasse, J., & Klagsbrun, M. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.8.2292 · Cited by 1,032
Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice
Bergers, G., Javaherian, K., Lo, K.-M., Folkman, J., & Hanahan, D. (1999) · Science · doi:10.1126/science.284.5415.808 · Cited by 988
Heparin Affinity: Purification of a Tumor-Derived Capillary Endothelial Cell Growth Factor
Shing, Y., Folkman, J., Sullivan, R., Butterfield, C., Murray, J., & Klagsbrun, M. (1984) · Science · doi:10.1126/science.6199844 · Cited by 933
Self-citationMatrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention
Stetler-Stevenson, W. G. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6870 · Cited by 842
Matrix metalloproteinases and metastasis
Kleiner, D. E., & Stetler-Stevenson, W. G. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800051097 · Cited by 701
Vacca, A., Ribatti, D., Presta, M., Minischetti, M., Iurlaro, M., Ria, R., Albini, A., Bussolino, F., & Dammacco, F. (1999) · Blood · doi:10.1182/blood.v93.9.3064 · Cited by 599
Unemori, E. N., Ferrara, N., Bauer, E. A., & Amento, E. P. (1992) · Journal of Cellular Physiology · doi:10.1002/jcp.1041530317 · Cited by 526
Herron, G. S., Banda, M. J., Clark, E. J., Gavrilovic, J., & Werb, Z. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35860-x · Cited by 525
Identification of an Inhibitor of Neovascularization from Cartilage
Moses, M. A., Sudhalter, J., & Langer, R. (1990) · Science · doi:10.1126/science.1694043 · Cited by 477
Self-citationTumor-promoting phorbol esters induce angiogenesis in vitro
Montesano, R., & Orci, L. (1985) · Cell · doi:10.1016/0092-8674(85)90104-7 · Cited by 464
Mignatti, P., Tsuboi, R., Robbins, E., & Rifkin, D. B. (1989) · The Journal of cell biology · doi:10.1083/jcb.108.2.671 · Cited by 453
Kähäri, V.-M., & Saarialho-Kere, U. (1999) · Annals of Medicine · doi:10.3109/07853899909019260 · Cited by 408
Levi, E., Fridman, R., Miao, H. Q., Ma, Y. S., Yayon, A., & Vlodavsky, I. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.14.7069 · Cited by 351
Murphy, A. N., Unsworth, E. J., & Stetler‐Stevenson, W. G. (1993) · Journal of Cellular Physiology · doi:10.1002/jcp.1041570219 · Cited by 351
Suzuki, M., Raab, G., Moses, M. A., Fernandez, C. A., & Klagsbrun, M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.50.31730 · Cited by 330
Self-citationThe Regulation of Neovascularization by Matrix Metalloproteinases and Their Inhibitors
Moses, M. A. (1997) · STEM CELLS · doi:10.1002/stem.150180 · Cited by 298
Self-citationType IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro
Schnaper, H. W., Grant, D. S., Stetler‐Stevenson, W. G., Fridman, R., D'Orazi, G., Murphy, A. N., Bird, R. E., Hoythya, M., Fuerst, T. R., French, D. L., et al. (1993) · Journal of Cellular Physiology · doi:10.1002/jcp.1041560204 · Cited by 289
Inhibition of angiogenesis by tissue inhibitor of metalloproteinase
Johnson, M. D., Kim, H. C., Chesler, L., Tsao‐Wu, G., Polverini, P. J., & Bouck, N. (1994) · Journal of Cellular Physiology · doi:10.1002/jcp.1041600122 · Cited by 288
Lamoreaux, W. J., Fitzgerald, M. E. C., Reiner, A., Hasty, K. A., & Charles, S. T. (1998) · Microvascular Research · doi:10.1006/mvre.1997.2056 · Cited by 278
Zucker, S., Mirza, H., Conner, C. E., Lorenz, A. F., Drews, M. H., Bahou, W. F., & Jesty, J. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980302)75:5<780::aid-ijc19>3.0.co;2-a · Cited by 270
Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3.
Anand‐Apte, B., Pepper, M. S., Voest, E. E., Montesano, R., Olsen, B. R., Murphy, G., Apte, S., & Zetter, B. R. (1997) · PubMed · Cited by 251
A secreted FGF-binding protein can serve as the angiogenic switch in human cancer
Czubayko, F., Liaudet-Coopman, E. D. E., Aigner, A., Tuveson, A. T., Berchem, G. J., & Wellstein, A. (1997) · Nature Medicine · doi:10.1038/nm1097-1137 · Cited by 237
Taraboletti, G., Garofalo, A., Belotti, D., Drudis, T., Borsotti, P., Scanziani, E., Brown, P. D., & Giavazzi, R. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.4.293 · Cited by 235
Troponin I is present in human cartilage and inhibits angiogenesis
Moses, M. A., Wiederschain, D., Wu, I., Fernandez, C. A., Ghazizadeh, V., Lane, W. S., Flynn, E., Sytkowski, A., Tao, T., & Langer, R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.2645 · Cited by 219
Self-citationDetermination of the number of endothelial cells in culture using an acid phosphatase assay
Connolly, D. T., Knight, M. B., Harakas, N. K., Wittwer, A. J., & Feder, J. (1986) · Analytical Biochemistry · doi:10.1016/0003-2697(86)90131-4 · Cited by 204
Matrix metalloproteinases and metastatic cancer.
Cockett, M. I., Murphy, G., Birch, M. L., Jp, O., Crabbe, T., At, M., Hart, I. R., & Aj, D. (1998) · PubMed · Cited by 120
Lozonschi, L., Sunamura, M., Kobari, M., Egawa, S., Ding, L., & Matsuno, S. (1999) · PubMed · Cited by 107
Isolation and characterization of an inhibitor of neovascularization from scapular chondrocytes.
Moses, M. A., Sudhalter, J., & Langer, R. (1992) · The Journal of Cell Biology · doi:10.1083/jcb.119.2.475 · Cited by 94
Self-citationBraunhut, S. J., & Moses, M. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36856-4 · Cited by 89
Self-citationDysregulated proteolytic balance as the basis of excess extracellular matrix in fibrotic disease
Peters, C. A., Freeman, M. R., Fernández, C. A., Shepard, J., Wiederschain, D., & Moses, M. A. (1997) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1997.272.6.r1960 · Cited by 81
Self-citationHodgson, J. (1995) · Nature Biotechnology · doi:10.1038/nbt0695-554 · Cited by 49
Cited by
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
How Matrix Metalloproteinases Regulate Cell Behavior
Sternlicht, M. D., & Werb, Z. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.463 · Cited by 3,959
“Although MMP2 does not appear to influence angiogenesis in the above model, its downregulation by targeted gene disruption and antisense methods does suppress tumorinduced angiogenesis in other models (T Itoh et al. 1998, Fang et al. 2000).”
BackgroundMatrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
Matrix metalloproteinases and tumor metastasis
Deryugina, E. I., & Quigley, J. P. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-7886-9 · Cited by 1,960
Vascular Endothelial Growth Factor and Angiogenesis
Hoeben, A., Landuyt, B., Highley, M. S., Wildiers, H., Van Oosterom, A. T., & De Bruijn, E. A. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.4.3 · Cited by 1,824
Metadata
- Authors
- Fang, J., Shing, Y., Wiederschain, D., Yan, L., Butterfield, C., Jackson, G., Harper, J., Tamvakopoulos, G., & Moses, M. A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2000-04-11
- Volume
- 97
- Issue
- 8
- Pages
- 3884-3889
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2083535354
- Cited by
- 393
- References
- 43
- FWCI
- 9.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.